HK1035665A1 - Therapeutic compositions (II) - Google Patents
Therapeutic compositions (II)Info
- Publication number
- HK1035665A1 HK1035665A1 HK01106060A HK01106060A HK1035665A1 HK 1035665 A1 HK1035665 A1 HK 1035665A1 HK 01106060 A HK01106060 A HK 01106060A HK 01106060 A HK01106060 A HK 01106060A HK 1035665 A1 HK1035665 A1 HK 1035665A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- patient
- physiologically acceptable
- therapeutic compositions
- acceptable ketosis
- ketosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10037198P | 1998-09-15 | 1998-09-15 | |
PCT/US1999/021015 WO2000015216A1 (en) | 1998-09-15 | 1999-09-15 | Therapeutic compositions (ii) |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1035665A1 true HK1035665A1 (en) | 2001-12-07 |
Family
ID=22279402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01106060A HK1035665A1 (en) | 1998-09-15 | 2001-08-28 | Therapeutic compositions (II) |
Country Status (18)
Country | Link |
---|---|
US (2) | US20010014696A1 (pt) |
EP (1) | EP1123094B1 (pt) |
JP (1) | JP2002524506A (pt) |
KR (1) | KR100805490B1 (pt) |
CN (1) | CN1273129C (pt) |
AT (1) | ATE359069T1 (pt) |
AU (1) | AU767238B2 (pt) |
BR (1) | BR9913680A (pt) |
CA (1) | CA2339941A1 (pt) |
DE (1) | DE69935799T2 (pt) |
DK (1) | DK1123094T3 (pt) |
ES (1) | ES2283133T3 (pt) |
HK (1) | HK1035665A1 (pt) |
NZ (1) | NZ509739A (pt) |
PT (1) | PT1123094E (pt) |
RU (1) | RU2242227C2 (pt) |
WO (1) | WO2000015216A1 (pt) |
ZA (1) | ZA200101260B (pt) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
WO2007115282A2 (en) | 2006-04-03 | 2007-10-11 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
DE60138019D1 (de) * | 2000-05-01 | 2009-04-30 | Accera Inc | Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung |
DK1648952T3 (en) | 2003-06-03 | 2018-05-28 | The Us Gov As Represented By The Department Of Health And Human Services | Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives |
EP1661574B1 (en) * | 2003-09-01 | 2017-04-19 | Earthus, Inc. | Beta-hydroxy short to medium chain fatty acid polymer |
US7132221B2 (en) * | 2003-09-12 | 2006-11-07 | Headway Technologies, Inc. | Method to print photoresist lines with negative sidewalls |
GB0410266D0 (en) * | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
US7485743B2 (en) | 2004-07-20 | 2009-02-03 | Btg International Limited | Oligomeric ketone compounds |
DK1796658T3 (en) * | 2004-09-21 | 2016-06-27 | Btg Int Ltd | dopaminergic mimetics |
GB0427145D0 (en) * | 2004-12-10 | 2005-01-12 | Ketocytonyx Inc | Compositions for use in surgery |
WO2007001883A2 (en) | 2005-06-20 | 2007-01-04 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
US7807718B2 (en) * | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
US8758740B2 (en) | 2007-03-30 | 2014-06-24 | Earthus, Inc | Composition for promoting ketone body production |
BRPI0811052A2 (pt) * | 2007-04-12 | 2015-01-27 | Univ Minnesota | Composições de proteção de isquemia/reperfusão e métodos de uso. |
WO2009052182A1 (en) | 2007-10-15 | 2009-04-23 | Jbs United, Inc. | Method for increasing performance of offspring |
CN101293831B (zh) * | 2007-04-27 | 2013-09-18 | 汕头大学 | 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途 |
PT2650379E (pt) * | 2007-07-31 | 2016-01-13 | Accera Inc | Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida |
TR201908522T4 (tr) * | 2008-01-04 | 2019-07-22 | The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. |
AU2009266869B2 (en) | 2008-07-03 | 2016-07-07 | Cerecin Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
US8105809B2 (en) | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
AU2010207597A1 (en) | 2009-01-24 | 2011-08-18 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
DK2521556T3 (en) * | 2010-01-08 | 2018-08-13 | Ionis Pharmaceuticals Inc | MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
WO2012010896A1 (en) | 2010-07-20 | 2012-01-26 | Phytopharm Plc | Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
EP3659595A1 (en) | 2012-11-05 | 2020-06-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ketone bodies to protect tissues from damage by ionizing radiation |
GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
US11566268B2 (en) | 2013-03-14 | 2023-01-31 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Process for producing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate |
KR102499654B1 (ko) | 2013-03-19 | 2023-02-13 | 유니버시티 오브 사우스 플로리다 | 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법 |
KR102554521B1 (ko) | 2014-02-20 | 2023-07-11 | 프레제니우스 카비 도이치란트 게엠베하 | 적혈구 제품, 혈장 및 혈소판의 보관을 위한 비-dehp 가소제를 갖는 의료용 컨테이너 및 시스템 구성요소 |
US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
US11166928B2 (en) * | 2016-12-21 | 2021-11-09 | Universitats-Kinderspital Beider Basel | Migraine prevention and treatment |
CN110248652B (zh) * | 2016-12-23 | 2023-05-26 | 鲁汶大学 | 3-羟基丁酸单独或组合用于治疗重症监护治疗 |
US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
GB2572185A (en) * | 2018-03-21 | 2019-09-25 | Chain Biotechnology Ltd | Pharmaceutical compositions |
US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
IT201900022854A1 (it) * | 2019-12-03 | 2021-06-03 | Dr Schaer S P A | Formulazione alimentare e prodotto alimentare da forno per la gestione della dieta chetogenica |
KR20240037239A (ko) | 2021-07-17 | 2024-03-21 | 케토스위스 아게 | 케톤체 또는 케톤 생성 화합물과 진통제 또는 항산화제의 조합 |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0522422A3 (en) * | 1991-07-01 | 1993-03-17 | Mitsubishi Kasei Corporation | Process for producing a biodegradable polymer |
JP2885261B2 (ja) * | 1993-05-17 | 1999-04-19 | 三菱瓦斯化学株式会社 | 3−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤 |
JP4598203B2 (ja) | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
DK2283834T3 (en) * | 1997-03-17 | 2016-08-15 | Btg Int Ltd | Therapeutic compositions comprising ketone compounds and precursors thereof |
DK1045642T3 (da) * | 1998-01-07 | 2003-03-03 | Metabolix Inc | Dyrefodersammensætninger |
DE69922206T2 (de) * | 1998-07-22 | 2005-11-24 | Metabolix, Inc., Cambridge | Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere |
-
1999
- 1999-09-15 BR BR9913680-5A patent/BR9913680A/pt not_active Application Discontinuation
- 1999-09-15 CA CA002339941A patent/CA2339941A1/en not_active Abandoned
- 1999-09-15 DK DK99946906T patent/DK1123094T3/da active
- 1999-09-15 WO PCT/US1999/021015 patent/WO2000015216A1/en active IP Right Grant
- 1999-09-15 AU AU59212/99A patent/AU767238B2/en not_active Ceased
- 1999-09-15 RU RU2001110097/15A patent/RU2242227C2/ru not_active IP Right Cessation
- 1999-09-15 PT PT99946906T patent/PT1123094E/pt unknown
- 1999-09-15 AT AT99946906T patent/ATE359069T1/de active
- 1999-09-15 ES ES99946906T patent/ES2283133T3/es not_active Expired - Lifetime
- 1999-09-15 NZ NZ509739A patent/NZ509739A/en not_active IP Right Cessation
- 1999-09-15 DE DE69935799T patent/DE69935799T2/de not_active Expired - Lifetime
- 1999-09-15 JP JP2000569800A patent/JP2002524506A/ja active Pending
- 1999-09-15 CN CNB998108375A patent/CN1273129C/zh not_active Expired - Fee Related
- 1999-09-15 KR KR1020017003343A patent/KR100805490B1/ko not_active IP Right Cessation
- 1999-09-15 EP EP99946906A patent/EP1123094B1/en not_active Expired - Lifetime
-
2001
- 2001-02-14 ZA ZA200101260A patent/ZA200101260B/en unknown
- 2001-03-06 US US09/799,124 patent/US20010014696A1/en not_active Abandoned
- 2001-08-28 HK HK01106060A patent/HK1035665A1/xx not_active IP Right Cessation
-
2003
- 2003-12-15 US US10/734,586 patent/US7351736B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69935799T2 (de) | 2007-12-27 |
CN1316902A (zh) | 2001-10-10 |
ATE359069T1 (de) | 2007-05-15 |
AU5921299A (en) | 2000-04-03 |
CA2339941A1 (en) | 2000-03-23 |
KR20010079830A (ko) | 2001-08-22 |
PT1123094E (pt) | 2007-06-28 |
BR9913680A (pt) | 2001-06-05 |
WO2000015216A1 (en) | 2000-03-23 |
EP1123094A1 (en) | 2001-08-16 |
EP1123094B1 (en) | 2007-04-11 |
RU2242227C2 (ru) | 2004-12-20 |
EP1123094A4 (en) | 2001-10-04 |
DE69935799D1 (de) | 2007-05-24 |
DK1123094T3 (da) | 2007-08-20 |
ES2283133T3 (es) | 2007-10-16 |
AU767238B2 (en) | 2003-11-06 |
KR100805490B1 (ko) | 2008-02-20 |
CN1273129C (zh) | 2006-09-06 |
ZA200101260B (en) | 2001-08-16 |
NZ509739A (en) | 2003-10-31 |
US7351736B2 (en) | 2008-04-01 |
JP2002524506A (ja) | 2002-08-06 |
US20010014696A1 (en) | 2001-08-16 |
US20040171671A1 (en) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1035665A1 (en) | Therapeutic compositions (II) | |
BE2018C038I2 (pt) | ||
IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
MY130157A (en) | Method of use for inhibiting bone loss and lowering serum cholesterol | |
ZA883602B (en) | Medicament | |
RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
RU2001110097A (ru) | Терапевтические композиции (ii) | |
IL99699A0 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
EP0777484A4 (en) | INTRAVENOUS ALENDRONATE FORMULATIONS | |
MX9805588A (es) | Administracion oral de cantidades efectivas de formas de acido hialuronico. | |
SE8704248D0 (sv) | Medical use | |
EP0315591A3 (en) | Physiologically active substances, a process for the preparation thereof and pharmaceutical compositions containing them | |
GR3032041T3 (en) | Idebenone compositions for treating Alzheimer's disease. | |
SE8500996D0 (sv) | Method of treatment | |
HU9303000D0 (en) | Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof | |
NZ303993A (en) | Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders | |
EG17992A (en) | Preparation of a medicament for arthritis and theumatism | |
HUT73500A (en) | Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf | |
Kaldor et al. | Enhancement of methyldopa metabolism with barbiturate | |
UA10301A (uk) | Спосіб лікуваhhя раку шлуhку | |
SU944583A1 (ru) | Способ реабилитации травматических поражений мышц | |
UA30251A (uk) | Спосіб лікування гіпертонії сфінктера одді у хворих на хронічний безкам'яний холецистит при поєднанні з підвищенням тонусу симпатичної нервової системи | |
UA30912A (uk) | Спосіб терапії хворих на хронічний обструктивний бронхіт | |
UA15281A (uk) | Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця | |
UA30184A (uk) | Спосіб рефлексотерапії хворих з віддаленими наслідками черепно-мозкової травми |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20110915 |